Dapagliflozin (Farxiga) appears to be no more effective than the "thiazide-like" diuretic metolazone at improving pulmonary congestion and fluid status in patients with acute heart failure (AHF), ...
Type 2 diabetes (T2D) is a growing epidemic in India. India has 101 million people with diabetes and 136 million with prediabetes, with disease onset occurring at much younger ages than in ...
WILMINGTON, Del.--(BUSINESS WIRE)--Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), ...
ZENITH-CKD is the first randomized trial comparing combined SGLT2 and endothelin A inhibition in patients with chronic kidney disease. Zibotentan, a selective endothelin A receptor antagonist, may ...
NEW ORLEANS, LA—Ever since sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to have beneficial effects in patients with heart failure, there have been questions about the underlying ...
LAS VEGAS – Dapagliflozin significantly improved glycemic control and was well tolerated among treatment-naïve patients with type 2 diabetes and those unresponsive to prior treatment with glimepiride ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...
AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared to ...
The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback